Literature DB >> 23584444

Characteristics of chronic GVHD after cord blood transplantation.

L F Newell1, M E D Flowers, T A Gooley, F Milano, P A Carpenter, P J Martin, C Delaney.   

Abstract

Most reports of chronic GVHD after cord blood transplantation (CBT) have utilized traditional diagnostic criteria. We used traditional criteria and National Institutes of Health (NIH) criteria prospectively to evaluate chronic GVHD in a cohort of 87 adult and pediatric recipients of single or double unrelated CBT for treatment of hematologic malignancies. Fifty-four patients developed traditionally defined chronic GVHD, for an estimated 2-year probability of 64%. Among 54 patients, 25 (46%) met the NIH criteria for persistent, recurrent or late acute GVHD at onset. Twenty-four (44%) had overlap chronic GVHD, including one who presented initially with late acute GVHD, and only seven (13%) had classic chronic GVHD, including one who also presented initially with late acute GVHD. Among patients who successfully discontinued all systemic immunosuppression (SI), the median time to discontinuation of corticosteroid treatment was 315 days (range 28-977), and the median time to discontinuation of all SI was 353 days (range 67-977). Chronic GVHD diagnosed by traditional criteria after CBT had a predominance of acute GVHD clinical features.

Entities:  

Mesh:

Year:  2013        PMID: 23584444      PMCID: PMC3795867          DOI: 10.1038/bmt.2013.48

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  34 in total

Review 1.  Immune regulatory cells in umbilical cord blood and their potential roles in transplantation tolerance.

Authors:  Young-June Kim; Hal E Broxmeyer
Journal:  Crit Rev Oncol Hematol       Date:  2010-08-19       Impact factor: 6.312

2.  Proliferative and cytotoxic responses of human cord blood T lymphocytes following allogeneic stimulation.

Authors:  G Risdon; J Gaddy; F B Stehman; H E Broxmeyer
Journal:  Cell Immunol       Date:  1994-03       Impact factor: 4.868

3.  Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation.

Authors:  Marco Mielcarek; Paul J Martin; Wendy Leisenring; Mary E D Flowers; David G Maloney; Brenda M Sandmaier; Michael B Maris; Rainer Storb
Journal:  Blood       Date:  2003-03-27       Impact factor: 22.113

4.  Acute graft-versus-host disease after unrelated donor umbilical cord blood transplantation: analysis of risk factors.

Authors:  Margaret L MacMillan; Daniel J Weisdorf; Claudio G Brunstein; Qing Cao; Todd E DeFor; Michael R Verneris; Bruce R Blazar; John E Wagner
Journal:  Blood       Date:  2008-11-07       Impact factor: 22.113

5.  Increasingly frequent diagnosis of acute gastrointestinal graft-versus-host disease after allogeneic hematopoietic cell transplantation.

Authors:  Paul J Martin; George B McDonald; Jean E Sanders; Claudio Anasetti; Frederick R Appelbaum; H Joachim Deeg; Richard A Nash; Effie W Petersdorf; John A Hansen; Rainer Storb
Journal:  Biol Blood Marrow Transplant       Date:  2004-05       Impact factor: 5.742

6.  Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial.

Authors:  Mary E D Flowers; Pablo M Parker; Laura J Johnston; Alice V B Matos; Barry Storer; William I Bensinger; Rainer Storb; Frederick R Appelbaum; Stephen J Forman; Karl G Blume; Paul J Martin
Journal:  Blood       Date:  2002-07-15       Impact factor: 22.113

7.  New classification of chronic GVHD: added clarity from the consensus diagnoses.

Authors:  M Arora; S Nagaraj; J Witte; T E DeFor; M MacMillan; L J Burns; D J Weisdorf
Journal:  Bone Marrow Transplant       Date:  2008-09-15       Impact factor: 5.483

8.  Umbilical cord blood transplantation after reduced-intensity conditioning for elderly patients with hematologic diseases.

Authors:  Naoyuki Uchida; Atsushi Wake; Shinsuke Takagi; Hisashi Yamamoto; Daisuke Kato; Yoshiko Matsuhashi; Tomoko Matsumura; Sachiko Seo; Naofumi Matsuno; Kazuhiro Masuoka; Eiji Kusumi; Koichiro Yuji; Shigesaburo Miyakoshi; Michio Matsuzaki; Akiko Yoneyama; Shuichi Taniguchi
Journal:  Biol Blood Marrow Transplant       Date:  2008-05       Impact factor: 5.742

9.  Feasibility of NIH consensus criteria for chronic graft-versus-host disease.

Authors:  B-S Cho; C-K Min; K-S Eom; Y-J Kim; H-J Kim; S Lee; S-G Cho; D-W Kim; J-W Lee; W-S Min; C-C Kim
Journal:  Leukemia       Date:  2008-10-02       Impact factor: 11.528

10.  Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients.

Authors:  H M Shulman; K M Sullivan; P L Weiden; G B McDonald; G E Striker; G E Sale; R Hackman; M S Tsoi; R Storb; E D Thomas
Journal:  Am J Med       Date:  1980-08       Impact factor: 4.965

View more
  12 in total

Review 1.  Cord blood transplantation: rewind to fast forward.

Authors:  A Dahlberg; F Milano
Journal:  Bone Marrow Transplant       Date:  2016-12-19       Impact factor: 5.483

2.  Cytokines in umbilical cord blood-derived cellular product: a mechanistic insight into bone repair.

Authors:  Mukta S Sane; Neha Misra; Omid Mohammad Mousa; Steve Czop; Huiyuan Tang; Larry T Khoo; Christopher D Jones; Soumyajit Banerjee Mustafi
Journal:  Regen Med       Date:  2018-10-22       Impact factor: 3.806

3.  The Anatomic Distribution of Skin Involvement in Patients with Incident Chronic Graft-versus-Host Disease.

Authors:  Jocelyn S Gandelman; John Zic; Anna K Dewan; Stephanie J Lee; Mary Flowers; Corey Cutler; Joseph Pidala; Heidi Chen; Madan H Jagasia; Eric R Tkaczyk
Journal:  Biol Blood Marrow Transplant       Date:  2018-09-13       Impact factor: 5.742

4.  Chronic graft versus host disease burden and late transplant complications are lower following adult double cord blood versus matched unrelated donor peripheral blood transplantation.

Authors:  J A Gutman; K Ross; C Smith; H Myint; C-K Lee; R Salit; F Milano; C Delaney; D Gao; D A Pollyea
Journal:  Bone Marrow Transplant       Date:  2016-07-11       Impact factor: 5.483

5.  An endpoint associated with clinical benefit after initial treatment of chronic graft-versus-host disease.

Authors:  Paul J Martin; Barry E Storer; Yoshihiro Inamoto; Mary E D Flowers; Paul A Carpenter; Joseph Pidala; Jeanne Palmer; Mukta Arora; Madan Jagasia; Sally Arai; Corey S Cutler; Stephanie J Lee
Journal:  Blood       Date:  2017-05-11       Impact factor: 22.113

6.  Single cord blood transplantation for acute myeloid leukemia patients aged 60 years or older: a retrospective study in Japan.

Authors:  Masamichi Isobe; Takaaki Konuma; Masayoshi Masuko; Naoyuki Uchida; Shigesaburo Miyakoshi; Yasuhiro Sugio; Shuro Yoshida; Masatsugu Tanaka; Yoshiko Matsuhashi; Norimichi Hattori; Makoto Onizuka; Nobuyuki Aotsuka; Yasushi Kouzai; Atsushi Wake; Takafumi Kimura; Tatsuo Ichinohe; Yoshiko Atsuta; Masamitsu Yanada
Journal:  Ann Hematol       Date:  2021-02-23       Impact factor: 3.673

7.  Risk Factors for Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation with Umbilical Cord Blood and Matched Sibling Donors.

Authors:  Aleksandr Lazaryan; Daniel J Weisdorf; Todd DeFor; Claudio G Brunstein; Margaret L MacMillan; Nelli Bejanyan; Shernan Holtan; Bruce R Blazar; John E Wagner; Mukta Arora
Journal:  Biol Blood Marrow Transplant       Date:  2015-09-11       Impact factor: 5.742

8.  Impact of sex incompatibility on the outcome of single-unit cord blood transplantation for adult patients with hematological malignancies.

Authors:  T Konuma; S Kato; J Ooi; M Oiwa-Monna; Y Ebihara; S Mochizuki; K Yuji; N Ohno; T Kawamata; N Jo; K Yokoyama; K Uchimaru; A Tojo; S Takahashi
Journal:  Bone Marrow Transplant       Date:  2014-02-17       Impact factor: 5.483

9.  IL-7 and SCF Levels Inversely Correlate with T Cell Reconstitution and Clinical Outcomes after Cord Blood Transplantation in Adults.

Authors:  Ioannis Politikos; Haesook T Kim; Sarah Nikiforow; Lequn Li; Julia Brown; Joseph H Antin; Corey Cutler; Karen Ballen; Jerome Ritz; Vassiliki A Boussiotis
Journal:  PLoS One       Date:  2015-07-15       Impact factor: 3.240

10.  Linezolid Induced Twice Pure Red Cell Aplasia in a Patient with Central Nervous System Infection after Allogeneic Stem Cell Transplantation.

Authors:  Wenqing Hu; Bing Shi; Lihui Liu; Shengke He; Liping Ye; DengMei Tian; Yongqing Zhang
Journal:  Iran J Pharm Res       Date:  2016       Impact factor: 1.696

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.